1. Pink Sheet

Brazil Considers Easier Path For Compulsory Licensing

President Is Unlikely To Sign Off Bill

 
• By Francesca Bruce

A bill amending Brazilian patent law to make compulsory licensing easier has passed the senate but still must be signed off by president Jair Bolsonaro.

BrazilMap_1200x675
Brazilian compulsory licensing bill awaits sign off from president

Proposals to facilitate compulsory licensing in Brazil extend beyond the COVID-19 crisis to other public health emergencies. While industry says the proposals are unnecessary and would damage investment in the sector, public health advocates argue they come as a result of pharma’s failure to engage with voluntary mechanisms to ensure demand for COVID-19 vaccines is met.

The most significant thing about the proposed provisions is that they address technology transfer needs by compelling the IP holder...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Legal & IP

More from Pink Sheet

CAR-T Therapy Trials Involving Chinese Labs Will Face Heightened US FDA Scrutiny

 
• By Michael McCaughan

The FDA wants to ensure participants in clinical trials involving genetic engineering done in China understand what the agency sees as privacy and security risks. The agency also wants cell therapy processing done outside of “hostile” countries.

New CDER Deputy Director Michael Davis Brings Psychedelic Drug Development Experience

 
• By Sue Sutter

Davis, a former FDA team leader in the Division of Psychiatry Products, rejoins the agency from the Usona Institute, which develops psychedelics. His background aligns with Commissioner Martin Makary’s goal of seeing new treatments approved for post-traumatic stress disorder.

EU Sees Unified Pathway For Drug/IVD Studies As Key To Future Research Investment

 
• By Vibha Sharma

As the EU tests the feasibility of a radical “all-in-one” procedure for combined drug and IVD studies, sponsors are being urged to approach this novel framework with flexibility and openness.